Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
about
The specialist physician's approach to rheumatoid arthritis in South AfricaMethotrexate treatment causes early onset of disease in a mouse model of Ross River virus-induced inflammatory disease through increased monocyte productionManaging the drug treatment of rheumatoid arthritis.Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-γ and IL-17A expressionsEfficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies.Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyAcute Hepatitis E Virus infection with coincident reactivation of Epstein-Barr virus infection in an immunosuppressed patient with rheumatoid arthritis: a case report.No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysisPersistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.Urinary tract infection mimicking acute mesenteric ischaemia in an immunocompromised patientThe potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?Bilateral Herpes Simplex Uveitis: Review of the Literature and Own Reports.Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in LiverMarkers of inflammation and oxidative stress studied in adjuvant-induced arthritis in the rat on systemic and local level affected by pinosylvin and methotrexate and their combination.N-feruloylserotonin in preventive combination therapy with methotrexate reduced inflammation in adjuvant arthritis.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].Coxiella burnetii, the agent of Q fever in Brazil: its hidden role in seronegative arthritis and the importance of molecular diagnosis based on the repetitive element IS1111 associated with the transposase gene.Genetic risk factors for serious infections in inflammatory bowel diseases.[Screening investigations during intensified immunosuppression in children and adolescents. Part 1].Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis.Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.Urinary tract infections in patients with rheumatoid arthritis.Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation.
P2860
Q26765122-CABEB9D8-76AC-4B15-9B45-79F9227E7295Q28535269-82504AAC-6CEA-45B1-A18A-E9E23639E2C0Q33611369-3ABCCDEC-FD58-400A-BC8E-EC3BDC82DCA5Q34473197-C86095EA-D961-45BE-8555-9242C7AFA730Q35054330-B64288D6-821E-4803-A0E3-15A4328F7BB6Q35782767-C8687952-659D-4637-9996-886EF4E22467Q35825073-F50FD6B9-D78D-4E2B-9A88-A9F9629126D2Q36300250-31099EFB-C4F9-4315-B523-2693961E7AFDQ36903117-1B8B9B05-29A8-4075-A732-E518CB301249Q37694129-520BDAAD-E3F2-4599-83C4-CBA6E7DCD045Q37852715-406C42C6-8EAA-464A-AF60-CA45AC255873Q38267703-BBEAD45C-65C6-4264-BE21-E6F8D4410182Q38785053-E990C8FA-8C0E-4C66-B584-E26850D15A2BQ38828358-0BA40FDD-7DF5-422A-A560-9A5F45EA7D91Q39156321-AFDA73FA-56F5-4843-BA88-7BA55B4EC375Q39177048-E7E55D90-0468-4EBC-85CF-1E9587B8A856Q39435409-5712C27E-6348-47AB-80B0-37823CB56820Q40116120-F2F981D0-88E8-48B4-8A78-C8DD52A9F7F5Q40175407-24205D5F-F325-4263-8B26-32018830B499Q40238572-04C64084-EA32-4F42-A1A0-41D803B29BBCQ40278995-43ADAB00-E69D-4957-B660-84844356151DQ40344947-34E8720E-1D18-4D44-A554-1457528BC9BAQ45182196-F2AEF392-EB32-433B-98F3-8386F718B0FBQ46299592-1F11919B-0A66-4DA2-9C52-B7DA100D572CQ46339578-4C50F31F-0032-4E8C-B87F-6B31A8FBCF12Q51200926-CF928E1C-D1EE-41B6-A955-C844DA489D51Q55268453-1B0BF336-2A28-43C8-8F0F-EC8CE043B603
P2860
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@en
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@nl
type
label
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@en
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@nl
prefLabel
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@en
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@nl
P2093
P356
P1433
P1476
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
@en
P2093
Catherine Aldridge
Gavin P Spickett
Lesley Kay
Sheila Waugh
P304
P356
10.1093/RHEUMATOLOGY/KEP101
P577
2009-05-15T00:00:00Z